Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.74 |
| ▸ | MAPT | P10636 | 4/20 | 0.74 |
| ▸ | GAA | P10253 | 4/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | GFER | P55789 | 2/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.74 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL425101 | 0.86 | PTGS2 (1.00) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL1594360 | 0.84 | RAB9A (0.68) | ALDH1A1MAPTGAAKDM4ESMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9017504 | 0.84 | PTGS2 (0.96) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL8420633 | 0.83 | PTGS2 (0.78) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL5992136 | 0.81 | PTGS2 (0.75) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL27389992 | 0.81 | PTGS2 (0.75) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL11142311 | 0.81 | PTGS2 (0.75) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL6898441 | 0.81 | PTGS2 (1.00) | PTGS2ALDH1A1MAPTGAAKDM4E | |
| SCHEMBL1965784 | 0.81 | MEN1 (0.80) | MAPTKDM4ESMN1; SMN2TDP1MEN1 | |
| SCHEMBL10906039 | 0.80 | PTGS2 (0.79) | PTGS2ALDH1A1MAPTGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816360-B2 | Microsomal triglyceride transfer protein (MTP) inhibitors, used for the treatment of atherosclerosis, pancreatitis, obesity, hypertriglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and non-insulin dependent diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-19 | — | — | US | disclosed |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | MEERPOEL LIEVEN | 2010-01-07 | — | — | US | disclosed |
| US-7504400-B2 | for the treatment of atherosclerosis, pancreatitis, obesity, hyper-triglyceridemia, hypercholesterolemia, hyperlipidemia, diabetes and type II diabetes; apolipoprotein B secretion inhibitors also for lipid lowering activity; compounds can selectively block MTP at the level of the gut wall in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-17 | — | — | US | disclosed |
| EP-1751131-B1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA NV (BE) | 2008-11-19 | — | — | EP | disclosed |
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | US | disclosed |
| EP-1751131-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005085226-A1 | MTP INHIBITING ARYL PIPERIDINES OR PIPERAZINES SUBSTITUTED WITH 5-MEMBERED HETEROCYCLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191383-A1 | Mtp inhibiting aryl piperydines or piperazines substituted with 5-membered heterocycles | APOB, PNLIP, LPL | PTGS2 702/4885ALDH1A1 2700/4885MAPT 4304/4885 |
| US-20100004263-A1 | MTP INHIBITING ARYL PIPERIDINES OR PEPERAZINES SUBSTITUTED WITH5-MEMBERED HETEROCYCLES | PNLIP, LPL, APOB | PTGS2 793/4885ALDH1A1 3136/4885MAPT 4512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.